Ascendis Pharma valuation
$271.19Change from previous close: −0.20%Absolute change: −$0.54
Valuation
The P/E ratio is 18.1. The average price target of 21 analysts is $315.20.
Data as of November 17, 2026
Ascendis Pharma compared with similar companies
Ascendis Pharma's P/E (trailing 12 months): 18.1, −53% against the median of a group of 7 similar companies (38.3).
| Metric | Ascendis Pharma | Median | 25th–75th percentile | Band |
|---|---|---|---|---|
| P/E (trailing 12 months) | 18.1 | 38.3 | 19.4 – 64.3 | Low |
| Forward P/E | 22.9 | 15.7 | 12.9 – 25.0 | Middle |
| EV/EBITDA | 46.5 | 15.6 | 11.1 – 27.9 | High |
| Price/book | 10.7 | 6.62 | 4.60 – 10.3 | High |
| Price/sales | 15.0 | 8.14 | 4.99 – 13.6 | High |
| Gross margin | 91.9% | 77.3% | 71.2% – 91.5% | High |
| Operating margin | 30.9% | 21.7% | -39.5% – 31.6% | Middle |
| Net margin | 72.9% | 6.7% | -19.9% – 30.2% | High |
| ROE | 132.2% | 8.3% | -1.5% – 88.3% | High |
| Debt/equity | 0.30 | 0.13 | 0.02 – 0.92 | Middle |
Group: the stock and up to 10 companies in the same industry (with fewer than 5, related industries too), same region first, with a similar size. Band: low = the lowest quarter of values in the group, middle = 25th to 75th percentile, high = the highest quarter. Negative multiples and multiples above 500 are excluded; a comparison needs at least 5 values. The group is recalculated nightly.
TickerLandia analysisHow it is calculated
Companies in the group: same industry, similar size
Other metrics
Valuation multiples
- Market cap
- $18.06B
- Enterprise value
- $17.55B
- EV/revenue
- 14.6
Profitability and growth
- ROA
- 13.0%
- ROIC
- 13.0%
- Revenue growth (year over year)
- 73.0%
- Earnings growth (year over year)
- -445.2%
Financial health
- Total cash
- $964.36M
- Total debt
- $447.8M
- Current ratio
- 2.89
- Quick ratio
- 2.22
- Altman Z-Score
- 9.26
- Piotroski F-Score
- 7.00
Dividends
- Dividend yield
- 0.0%
- Payout ratio
- 0.0%
Analysts and estimates
- Average price target
- $315.20
- Median price target
- $314.79
- High price target
- $355.02
- Low price target
- $273.24
- Analysts with a price target
- 21
- Consensus
- Strong buy
- Forward EPS
- $12.04
- EPS estimate, current year
- $15.98
Shares and trading
- Beta
- 0.49
- Average volume
- 733.47K
- Shares outstanding
- 65.6M
- Float
- 65.56M
- Institutional ownership
- 101.0%
- Insider ownership
- 0.9%
- Short interest (% of float)
- 5.4%
- Short ratio (days)
- 4.24
